Purification that powers progress.

We believe that innovation in purification can unlock breakthroughs in medicine. By reimagining chromatography with scalable, high-performance membranes, we’re helping biopharma teams deliver therapies that improve lives around the world. Better purification means better outcomes.

Founded by Drs. Scott Husson and Jinxiang Zhou in 2013, in Greenville, South Carolina, the idea for the company was inspired by research from over a decade of investigation at Clemson University.

In 2022, Purilogics became a part of Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions.

Purilogics develops and produces industry-leading membrane technologies for the rapidly growing biopharmaceutical industry. Our proprietary products are designed for use in rapid drug purification, from research to manufacturing grade.

Our Story

The newly defined Donaldson Life Sciences division is building a portfolio of biopharma innovations to provide cutting-edge technologies that simplify and accelerate development and production of therapeutics.

We are leveraging Donaldson’s over 100 year legacy as a world leader in providing filtration solutions and customer-centric service. We solve the world's most complex filtration challenges, and now are working to revolutionize solutions for biopharmaceutical applications.

Our strategy is underpinned by developing critical filtration, purification, and separation technologies that service the discovery, development, and GMC production of biopharmaceuticals. Isolere Bio, Purilogics, Solaris Biotech, and Univercells Technologies work together to provide differentiated solutions for genetic medicine bioprocessing while also consolidating multiple steps in the bioprocessing value-chain. We work with you, innovate, and deliver.